New combo therapy aims to halt multiple myeloma progression
NCT ID NCT01562405
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times
Summary
This early-phase study tests a new drug called sotatercept (ACE-011) combined with two standard treatments (lenalidomide or pomalidomide plus dexamethasone) in 33 adults with multiple myeloma that has returned or not responded to prior therapy. The main goal is to find the safest dose of sotatercept and begin to see if the combination can shrink tumors and slow disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Massachusetts General Hosptial
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.